Josh Disbrow

Josh Disbrow has been in the life sciences industry for nearly twenty-five years across pharmaceuticals, diagnostics, and medical devices. Josh co-founded Aytu BioPharma in 2015 and took the company public, having led Aytu’s listing on NASDAQ in 2017.

Prior to co-founding Aytu, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE), a clinical-stage biotechnology company developing anti-inflammatory biological therapies. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals, a private specialty pharmaceutical company.

Josh joined Arbor Pharmaceuticals as the company’s second employee and oversaw the launch and subsequent growth of the company’s commercial operations. Josh led the commercial organization since the company’s inception and led the launch of the company’s first product, subsequently launching numerous products and scaling the commercial organization across sales, marketing, managed care, sales training, and national accounts. In less than five years, Arbor grew from a company from the pre-commercialization stage and grew product sales to over $250 million.

Prior to joining Arbor, he served as the Director of Marketing at LipoScience (NASDAQ: LPDX), a specialty cardiovascular diagnostic company later acquired by LabCorp (NYSE: LH). Previously, Josh was in sales leadership at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices.

Josh began his career as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). Josh currently sits on the Board of Directors and is the Chair of the Nominating and Governance Committee of Zynex, Inc. (NASDAQ: ZYXI), a medical device company focused on electrotherapy and pain management. He holds a Bachelor of Science in Management from North Carolina State University and a Master of Business Administration from Wake Forest University.